Home > Haematology > EHA 2019 > Lymphoid Malignancies > Venetoclax-obinutuzumab combination elicits high response rates in CLL

Venetoclax-obinutuzumab combination elicits high response rates in CLL

Presented By
Dr Kirsten Fischer, University of Cologne, Germany
Conference
EHA 2019
Trial
Phase 3, CLL14
Previously untreated patients with chronic lymphocytic leukaemia (CLL) and coexisting conditions who received fixed-duration venetoclax plus obinutuzumab had better survival outcomes compared with fixed-duration chemoimmunotherapy, showed results from the international, open-label, phase 3 CLL14 trial [1, 2]. Dr Kirsten Fischer (University of Cologne, Germany) presented the CLL14 trial. The trial included 432 previously untreated patients with CLL and coexisting conditions, and patients were randomly assigned treatment with fixed-duration venetoclax plus obinutuzumab (n=216) or fixed-duration chlorambucil plus obinutuzumab (n=216). Venetoclax rapidly induces apoptosis of CLL by selective inhibition of BCL2, a protein that regulates cell death and is overexpressed in CLL cells. Obinutuzumab is an anti-CD20 monoclonal antibody that is able...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on